IDx LLC’s First medical device to use artificial intelligence to detect greater than a mild level of the eye disease diabetic retinopathy in adults

IDx LLC, with assistance from Hogan Lovells, achieved a major grant of De Novo classification from the U.S. Food and Drug Administration for the novel artificial...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Surface Oncology’s $119.5 Million Initial Public Offering

Goodwin advised Surface Oncology, Inc. (Surface) on the pricing of its initial public offering Surface Oncology, Inc. (“Surface”) (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation antibody...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here